LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
== Cost == Costs run up to US$2,000 per treatment session. Multiple sessions are normal. One business charges US$50,000 for the first two months. Patients pay the full cost out of pocket, because it is an unproven therapy that is not covered by health insurance.
(WINNER) The contestant won the whole competition. (WIN) The contestant won the Main Heat challenge. (HIGH) The contestant had one of the best dishes for that week. (IN) The contestant performed well enough to move on to the next week. (LOW) The contestant had one of the bottom dishes for that week, but was not eliminated. (OUT) The contestant was eliminated for worst dish.
Hyperinsulinism has also been implicated as a contributing factor in the excessive production of androgens in polycystic ovary syndrome. The principal treatments of hyperinsulinism due to insulin resistance are measures that improve insulin sensitivity, such as weight loss, physical exercise, and drugs such as thiazolidinediones or metformin.
=== PhD program === The Graduate Division of Biomedical Sciences hosts an "umbrella" PhD program that is not confined to a specific department. In 2023, the program had 39 matriculants. Students undertake three lab rotations before selecting a mentor. A concentration in clinical investigation is offered for both PhD and MD/PhD candidates. PhD students receive full tuition remission, a stipend, and subsidized housing.
== Perfluoroaromatic compounds == Perfluoroaromatic compounds contain only carbon and fluorine, like other fluorocarbons, but also contain an aromatic ring. The three most important examples are hexafluorobenzene, octafluorotoluene, and octafluoronaphthalene.
Sources: en.wikipedia.org
=== Plan-generate-test paradigm === The plan-generate-test paradigm is the basic organization of the problem-solving method, and is a common paradigm used by both Heuristic Dendral and Meta-Dendral systems. The generator (later named CONGEN) generates potential solutions for a particular problem, which are then expressed as chemical graphs in Dendral. However, this is feasible only when the number of candidate solutions is minimal. When there are large numbers of possible solutions, Dendral has to find a way to put constraints that rules out large sets of candidate solutions. This is the primary aim of Dendral planner, which is a “hypothesis-formation” program that employs “task-specific knowledge to find constraints for the generator”. Last but not least, the tester analyzes each proposed candidate solution and discards those that fail to fulfill certain criteria. This mechanism of plan-generate-test paradigm is what holds Dendral together.
=== Subsidiaries === 2GO Express, Inc. – Provides land, air, and sea transportation including courier services, general cargo, sea cargo services, and last-mile delivery for e-commerce. It operates a nationwide network of retail outlets and partner agents and partners with FedEx for international express services. 2GO Logistics, Inc. – Provides transportation, warehousing, cross-docking, trucking, domestic freight, and inventory management solutions nationwide. Kerry Logistics (Phils.), Inc. (KLPI) – A joint venture with Kerry Logistics Network Limited of Hong Kong, offering domestic and international freight forwarding, warehousing, distribution, customs brokerage, project logistics, and handling of dangerous goods. 2GO Land Transport, Inc. – Provides cargo hauling and forwarding via trucks, container vans, and closed vans. 2GO Retail – Offers domestic parcel delivery, FedEx international services, and 2GO Travel ticket sales through retail outlets and partner agents. Special Container and Value Added Services, Inc. (SCVASI) – Provides cold chain and liquid bulk transport solutions, including temperature-controlled vans and ISO tanks for FCL and LCL shipments, as well as project logistics for industries such as infrastructure, power, telecommunications, mining, and property. 2GO operates passenger and freight services connecting major ports across the Philippines, linking Luzon, the Visayas, and Mindanao.
== Consumer acceptance == Historically, consumers paid little attention to food technologies. Nowadays, the food production chain is long and complicated and food technologies are diverse. Consequently, consumers are uncertain about the determinants of food quality and find it difficult to understand them. Now, acceptance of food products very often depends on perceived benefits and risks associated with food. Popular views of food processing technologies matter. Especially innovative food processing technologies often are perceived as risky by consumers. Acceptance of the different food technologies varies. While pasteurization is well recognized and accepted, high pressure treatment and even microwaves often are perceived as risky. Studies by the Hightech Europe project found that traditional technologies were well accepted in contrast to innovative technologies. Consumers form their attitude towards innovative food technologies through three main mechanisms: First, through knowledge or beliefs about risks and benefits correlated with the technology; second, through attitudes based on their own experience; and third, through application of higher order values and beliefs. A number of scholars consider the risk-benefit trade-off as one of the main determinants of consumer acceptance, although some researchers place more emphasis on the role of benefit perception (rather than risk) in consumer acceptance.
By August 2000, the United States' National Intelligence Estimate argued that the movement had failed due to democratic backsliding, corruption, and disease outbreaks. The weekend of September 28, 1998, some 470 participants attended the African Renaissance Conference in Johannesburg. The next year, a book titled African Renaissance was released, with thirty essays arranged under topics corresponding to the conference's breakout sessions: "culture and education, economic transformation, science and technology, transport and energy, moral renewal and African values, and media and telecommunications." Mbeki, the keynote speaker at the opening plenary session of the conference, wrote the book's prologue. Other figures associated with the African Renaissance and the new generation of African leaders are President Yoweri Museveni of Uganda and President Paul Kagame of Rwanda.
A gas panel or gas manifold is the control equipment for supplying the breathing gas to the divers. Primary and reserve gas is supplied to the panel through shutoff valves from a low-pressure compressor or high-pressure storage cylinders ("bombs", "bundles", "quads", or "kellys"). The gas pressure may be controlled at the panel by an industrial pressure regulator, or it may already be regulated closer to the source (at the compressor, or at the storage cylinder outlet). The supply gas pressure is monitored on a gauge at the panel, and an over-pressure valve is fitted in case the supply pressure is too high. The gas panel may be operated by the diving supervisor if the breathing gas is air or a fixed ratio premix, but if the composition must be controlled or monitored during the dive it is usual for a dedicated gas panel operator, or "gas man" to do this work. There is a set of valves and gauges for each diver to be supplied from the panel. These include:
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.